ABOUT US
Our Mission & Commitments
At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe
Our Mission
Cerus will establish INTERCEPT™ as the standard of care for transfused blood components globally and enable our customers to do everything in their power to deliver safe and effective blood products to patients.
Our Commitments
With a nearly three-decade history in the field of transfusion medicine, Cerus is dedicated to:
Safeguarding the World’s Blood Supply
Chronic blood shortages, emerging pathogens and increasing risk of transfusion transmitted Infections (TTIs) have heightened the need for blood safety and availability. Cerus is dedicated solely to safeguarding the world’s blood supply and providing innovative solutions to improve blood safety, access and patient survival.
Offering Inventive Solutions for Blood Safety and Access
Cerus’ INTERCEPT™ Blood System is the leading pathogen inactivation technology for ensuring the safety of the blood supply.1,2,3,4 We are taking advantage of the most extensive scientific and clinical data in the blood transfusion space to develop next generation technologies to expand our portfolio of blood products.
Going Beyond the Technology to Be a Truly Reliable Partner
We collaborate and partner with many of the world’s leading blood centres and hospitals and are committed to their success. By applying our expertise in all aspects of the blood supply chain - from operational processes to transfusion practices – we help them become more proficient in achieving our shared goal of safer, faster and better patient care.
You may also be interested in
- Platelet Additive Solutions and Pathogen Reduction Impact on Transfusion Safety, Patient Management and Platelet Supply; Georges Andreu; Transfusion Medicine Reviews 39 (2025) 150875
- Therapeutic efficacy and safety of pathogen-reduced platelet components: Results of a meta-analysis of randomized controlled trials; J Cid et al; Vox Sang. 2024 Mar;119(3):203-211. doi: 10.1111/vox.13573. Epub 2024 Jan 5.
- Assessing the inactivation capabilities of two commercially available platelet component pathogen inactivation systems: effectiveness at end of shelf life. Carl P. McDonald, Vox San 2021 Apr;116(4):416-424.doi: 10.1111/vox.13040.
- Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies. Carina Arcas Otero; Transfus Apher Sci. 2022 Jun;61(3):103359.
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19, and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT™ process. For a full list of warnings, precautions for use and pathogens inactivated, please refer to the Technical Data Sheet and Instructions for Use found in the resource section of this website.